| HOME >> MEDICINE >> TECHNOLOGY |
$ (9,486)
$ 170,972
$ 514,118+ Interest expense, as defined108,174
67,439
284,448
124,617+ Provision for income taxes44,710
95
136,484
44,605+ Non-cash stock-based compensation expense
5,562
3,662
21,499
13,072+ Depreciation12,088
5,045
34,654
14,727+ Amortization of intangible assets172,230
141,194
652,920
312,172+ Permitted R&D expenses—
—
26,400
11,500+ (Gain) on sale of assets—
—
—
(393,095)+ PGP Acquisition costs—
42,808
21,912
60,520+ Write-off of fair value step-up on acquired inventories
—
73,493
105,504
73,493+ Other permitted add-backs377
33,133
31,424
33,133Adjusted EBITDA of WC plc, as defined$ 358,587
$ 357,383
$ 1,486,217
$ 808,862+ Expenses of WC plc and other37,508
12,212
50,118
22,126Adjusted EBITDA of Warner Chilcott Holdings Company III, Limited, as defined$ 396,095$ 369,595$ 1,536,335$ 830,988Note: Warner Chilcott Holdings Company III, Limited and certain of its subsidiaries are parties to our senior secured credit facilities. Warner Chilcott plc is not a party to these agreements. Certain expenses included in Warner Chilcott plc's consolidated operating results are not deducted in arriving at Adjusted EBITDA for Warner Chilcott Holdings Company III, Limited and its subsidiaries. WARNER CHILCOTT PUBLIC LIMITED COMPANYREVENUE BY PRODUCT(In millions of U.S. dollars)(Unaudited)Quarter EndedYear EndedDec-31-10Dec-31-09Dec-31-10Dec-31-09Women's Healthcare
'/>"/>
| SOURCE Warner Chilcott plc Copyright©2010 PR Newswire. All rights reserved |